Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 5/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GPR39 | O43194 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825498 | 0.88 | GPR119 (0.47) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12825341 | 0.85 | GPR119 (0.48) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16592887 | 0.84 | PANK3 (0.48) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2349007 | 0.82 | KDM4E (0.51) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL29514660 | 0.82 | KDM4E (0.54) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3048925 | 0.82 | KDM4E (0.54) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14844043 | 0.82 | SMO (0.56) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3592250 | 0.81 | KDM4E (0.54) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3051541 | 0.80 | CNR2 (0.54) | GPR119PANK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7493026 | 0.79 | PANK3 (0.52) | GPR119PANK3KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | GPR119 1043/4885PANK3 1186/4885KDM4E 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.